Shingrix (Zostavax) Market Report 2026

Shingrix (Zostavax) Market Overview

• The Shingrix (Zostavax) market growth in the historic period has been driven by increasing awareness of shingles complications, aging global population growth • Market expansion is supported by increasing adult vaccination coverage targets, rising healthcare spending on preventive care • Growth Driver: Growing Adoption Of Vaccination Drives The Market Growth • Market Trend: Innovative Non-Live, Recombinant Subunit Vaccines Enhance Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Shingrix (Zostavax) Market?

Shingrix (Zostavax) refers to a vaccine designed to prevent shingles (herpes zoster), a painful rash caused by the reactivation of the varicella-zoster virus. It is used for immunizing adults, particularly those aged 50 and older, to reduce the risk of developing shingles and its complications. The main types of formulation in shingrix (zostavax) are recombinant vaccines (shingrix) and live-attenuated vaccines (zostavax). Recombinant vaccine (shingrix) refers to a non-live vaccine developed using recombinant DNA technology to prevent shingles, which stimulates the immune system by introducing a protein from the varicella-zoster virus, providing strong protection against the disease. The indications include shingles prevention and post-herpetic neuralgia with distribution channels such as hospital pharmacy and retail pharmacy.

What Is The Shingrix (Zostavax) Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adult vaccination coverage targets, rising healthcare spending on preventive care, expansion of recombinant vaccine pipelines, growing government-supported immunization initiatives, increasing focus on reducing post-herpetic neuralgia burden. Major trends in the forecast period include increasing adoption of recombinant vaccine platforms, rising focus on adult immunization programs, growing demand for long-lasting shingles protection, expansion of cold-chain optimized vaccine distribution, enhanced emphasis on vaccine safety and efficacy.

Global Shingrix (Zostavax) Market Segmentation

1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax) 2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy

What Is The Driver Of The Shingrix (Zostavax) Market?

The growing adoption of vaccination is expected to propel the growth of the shingrix (zostavax) market going forward. Vaccination refers to the process of administering a vaccine to stimulate the body's immune system to recognize and fight specific pathogens. The growing adoption of vaccination is attributed to increased awareness of its effectiveness in preventing diseases, reducing disease burden, and the development of safe and accessible vaccines. Public health campaigns, improved healthcare infrastructure, and global vaccination initiatives also contribute to its widespread acceptance. Shingrix (Zostavax) is beneficial for vaccination by providing effective protection against shingles and its complications. It is particularly beneficial for adults over 50, significantly reducing the risk of shingles recurrence and post-herpetic neuralgia. For instance, in May 2024, according to a study published by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, the shingles vaccinations covered by Medicare Part D increased by 46% in the year following the IRA policy's implementation in January 2023. Therefore, the growing adoption of vaccination is driving the growth of the shingrix (zostavax) industry.

Key Players In The Global Shingrix (Zostavax) Market

Major companies operating in the shingrix (zostavax) market are GSK plc

Global Shingrix (Zostavax) Market Trends and Insights

Major companies operating in the shingrix (zostavax) market are focusing on developing innovative solutions, such as non-live, recombinant subunit adjuvanted vaccines, to meet the rising demand for safer and more effective immunization, especially driven by age-related immune decline and the need for options in immunocompromised populations. A non-live, recombinant subunit adjuvanted vaccine contains specific protein components (antigens) of a pathogen, combined with an adjuvant to boost the immune response, unlike traditional live-attenuated vaccines that use weakened forms of the whole virus. For instance, in 2023, GSK plc, a UK-based biopharmaceutical company, launched Shingrix (Recombinant Zoster Vaccine, RZV) in India. This vaccine is non-live, given intramuscularly in two doses, and consists of the glycoprotein E antigen plus GSK’s proprietary AS01B adjuvant system. Shingrix stimulates a strong and durable immune response, overcoming the decline in immunity in older adults, and offers very high efficacy (up to ~97%).

What Are Latest Mergers And Acquisitions In The Shingrix (Zostavax) Market?

In October 2023, Chongqing Zhifei, a China-based biotechnology company that specializes in the development, manufacturing, and distribution of vaccines, partnered with GSK plc. With this partnership, GSK plc aims to expand the market reach of its top-selling shingles vaccine, shingrix, in China, the world’s second-largest pharmaceutical market, by spending. GSK plc, a UK-based pharmaceutical industry company that manufactures shingrix (zoster vaccine recombinant).

Regional Insights

North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Shingrix (Zostavax) Market?

The shingrix (zostavax) market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Shingrix (Zostavax) Market Report 2026?

The shingrix (zostavax) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the shingrix (zostavax) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.